Skip to content
2000
Volume 23, Issue 2
  • ISSN: 1570-162X
  • E-ISSN: 1873-4251

Abstract

Background

Modern antiretroviral therapy (ART) prevents disease progression in people living with HIV. Due to the increasing age of people living with HIV, the detection and management of comorbidities has become more important.

Objective

In this study, we aimed to detect the prevalence of nonalcoholic fatty liver disease (NAFLD) and associated risk factors among people living with HIV followed up in our center.

Methods

This single-center, cross-sectional study included people living with HIV, on ART for ≥1 year and virologic suppression for ≥6 months, presenting for routine follow-up between October 1, 2021, and April 1, 2022. Participants with a concurrent etiology for hepatic steatosis were excluded. Transient elastography (TE) was performed. NAFLD was defined as a controlled attenuation parameter (CAP) ≥248 dB/m; significant fibrosis (≥F2) was defined as liver stiffness measurement ≥7.1 kPa.

Results

A total of 102 people living with HIV (84% men; median age, 39 years (IQR 33-52.5)) were enrolled. The treatment regimen of all participants included a nucleos(t)ide reverse transcriptase inhibitor and an integrase strand transfer inhibitor. TE analysis indicated NAFLD in 28 (27.5%) and fibrosis in 9 (8.8%; 6 with NAFLD) participants. In multivariable analysis, type two diabetes (OR:5.7 (95% CI 1.4-22.2), =0.013), larger waist circumference (OR:1.1 (95% CI 1.03-1.16), =0.007), higher alanine aminotransferase (OR:1.05 (95% CI 1.01-1.09), =0.018), and higher thyroid stimulating hormone (OR:3.1 (95% CI 1.4-6.8), =0.005) were independently associated with NAFLD.

Conclusion

We observed a significant prevalence of NAFLD among people living with HIV followed up in our center. The high prevalence of NAFLD in our sample mirrors that of the general population, likely due to rising rates of metabolic dysfunction. Our findings highlight the importance of timely screening and implementation of management strategies for NAFLD in this population.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X340918250312040500
2025-03-24
2025-09-18

  • From This Site

    /content/journals/chr/10.2174/011570162X340918250312040500
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SaagM.S. BensonC.A. GandhiR.T. HoyJ.F. LandovitzR.J. MugaveroM.J. SaxP.E. SmithD.M. ThompsonM.A. BuchbinderS.P. RioD.C. EronJ.J.Jr FätkenheuerG. GünthardH.F. MolinaJ.M. JacobsenD.M. VolberdingP.A. Antiretroviral drugs for treatment and prevention of hiv infection in adults.JAMA2018320437939610.1001/jama.2018.843130043070
     [Google Scholar]
  2. ParasharS. CollinsA.B. MontanerJ.S.G. HoggR.S. MilloyM.J. Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs.Curr. Opin. HIV AIDS201611550751310.1097/COH.000000000000029727254749
     [Google Scholar]
  3. SmitM. BrinkmanK. GeerlingsS. SmitC. ThyagarajanK. SighemA. WolfD.F. HallettT.B. Future challenges for clinical care of an ageing population infected with HIV: A modelling study.Lancet Infect. Dis.201515781081810.1016/S1473‑3099(15)00056‑026070969
     [Google Scholar]
  4. GrossoT.M. AlcamíJ. ArribasJ.R. MartínM. SeretiI. TarrP. CahnP. ClotetB. SuedO. NegredoE. HIV and aging, biological mechanisms, and therapies: What do we know?AIDS Rev.2022242798610.24875/AIDSRev.2100008535901108
     [Google Scholar]
  5. MorseC.G. Fatty liver disease in HIV.AIDS201731111633163510.1097/QAD.000000000000152528657965
     [Google Scholar]
  6. NavarroJ. HIV and liver disease.AIDS Rev.2022252879635901073
     [Google Scholar]
  7. BlochM. JohnM. SmithD. RasmussenT.A. WrightE. Managing HIV-associated inflammation and ageing in the era of modern ART.HIV Med.202021S3Suppl. 321610.1111/hiv.1295233022087
     [Google Scholar]
  8. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J. Hepatol.20166461388140210.1016/j.jhep.2015.11.00427062661
     [Google Scholar]
  9. ChalasaniN. YounossiZ. LavineJ.E. CharltonM. CusiK. RinellaM. HarrisonS.A. BruntE.M. SanyalA.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the american association for the study of liver diseases.Hepatology201867132835710.1002/hep.2936728714183
     [Google Scholar]
  10. RatziuV. BellentaniS. Cortez-PintoH. DayC. MarchesiniG. A position statement on NAFLD/NASH based on the EASL 2009 special conference.J. Hepatol.201053237238410.1016/j.jhep.2010.04.00820494470
     [Google Scholar]
  11. YounossiZ.M. GolabiP. PaikJ.M. HenryA. DongenV.C. HenryL. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review.Hepatology20237741335134710.1097/HEP.000000000000000436626630
     [Google Scholar]
  12. DeğertekinB. TozunN. DemirF. SöylemezG. ParkanS. GürtayE. MutluD. ToramanM. SeymenoğluT.H. The changing prevalence of non-alcoholic fatty liver disease (NAFLD) in turkey in the last decade.Turk. J. Gastroenterol.202132330231210.5152/tjg.2021.2006234160360
     [Google Scholar]
  13. YilmazY. KaniH.T. DemirtaşC.O. KayaE. SapmazA.F. QutranjiL. AlkayyaliT. BatunK.D. BatmanM. ToyB. ÇiftaslanA. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.Turk. J. Gastroenterol.2019301089289810.5152/tjg.2019.1907231258138
     [Google Scholar]
  14. MuthiahM.D. SanyalA.J. Burden of disease due to nonalcoholic fatty liver disease.Gastroenterol. Clin. North Am.202049112310.1016/j.gtc.2019.09.00732033757
     [Google Scholar]
  15. OngJ.P. PittsA. YounossiZ.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.J. Hepatol.200849460861210.1016/j.jhep.2008.06.01818682312
     [Google Scholar]
  16. TackeF. HornP. WongV.W-S. RatziuV. BugianesiE. FrancqueS. Zelber-SagiS. ValentiL. RodenM. SchickF. Yki-JärvinenH. GastaldelliA. VettorR. FrühbeckG. DickerD. EASL–EASD–EASO Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive summary.Diabetologia202467112375239210.1007/s00125‑024‑06196‑338869512
     [Google Scholar]
  17. ChenV.L. MorganT.R. RotmanY. PattonH.M. CusiK. KanwalF. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance.Hepatology202481131232010.1097/HEP.000000000000111239422487
     [Google Scholar]
  18. Manzano-NunezR. Rivera-EstebanJ. NavarroJ. BañaresJ. SenaE. SchattenbergJ.M. LazarusJ.V. CurranA. PericàsJ.M. Uncovering the NAFLD burden in people living with HIV from high and middle income nations: A meta-analysis with a data gap from Subsaharan Africa.J. Int. AIDS Soc.2023263e2607210.1002/jia2.2607236924219
     [Google Scholar]
  19. SarıgülF. DenizM. Prevalence and related risk factors of non-alcoholic fatty liver disease in HIV/AIDS patients.Klimik Derg.2021341505510.36519/kd.2021.09
     [Google Scholar]
  20. LeeS.S. ParkS.H. Radiologic evaluation of nonalcoholic fatty liver disease.World J. Gastroenterol.201420237392740210.3748/wjg.v20.i23.739224966609
     [Google Scholar]
  21. WangC.C. ChaoY.C. Letter: HIV - associated NAFLD - more questions than answers?Aliment. Pharmacol. Ther.201541991210.1111/apt.1313325846390
     [Google Scholar]
  22. BuscaC. Sánchez-CondeM. RicoM. RosasM. ValenciaE. MorenoA. MorenoV. Martín-CarboneroL. MorenoS. Pérez-ValeroI. BernardinoJ.I. ArribasJ.R. GonzálezJ. OlveiraA. CastilloP. AbadíaM. GuerraL. MendezC. MontesM.L. Assessment of noninvasive markers of steatosis and liver fibrosis in human immunodeficiency virus-monoinfected patients on stable antiretroviral regimens.Open Forum Infect. Dis.202297ofac27910.1093/ofid/ofac27935873289
     [Google Scholar]
  23. KuchayM.S. ChoudharyN.S. SharmaD. KrishanS. MishraS.K. WasirJ.S. SinghM.K. SarafN. DhampalwarS. SudR. Diagnostic accuracy and optimal cut-off of controlled attenuation parameter for the detection of hepatic steatosis in indian population.J. Clin. Exp. Hepatol.202212389389810.1016/j.jceh.2021.10.00335677514
     [Google Scholar]
  24. EACS Guidelines v12.0.2023Available from: https://www.eacsociety.org/media/guidelines-12.0.pdf
  25. AlbertiK.G.M.M. ZimmetP. ShawJ. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation.Diabet. Med.200623546948010.1111/j.1464‑5491.2006.01858.x16681555
     [Google Scholar]
  26. American Diabetes Association Professional Practice C. 2. Classification and Diagnosis of Diabetes: Standards of medical care in diabetes—2022.Diabetes Care202245Suppl. 1S17S3810.2337/dc22‑S002
     [Google Scholar]
  27. YilmazY. ErenF. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease.Eur. J. Gastroenterol. Hepatol.201426111292129510.1097/MEG.000000000000018425171027
     [Google Scholar]
  28. ChangP.E. GohG.B. NguJ.H. TanH.K. TanC.K. Clinical applications, limitations and future role of transient elastography in the management of liver disease.World J. Gastrointest. Pharmacol. Ther.2016719110610.4292/wjgpt.v7.i1.9126855815
     [Google Scholar]
  29. KarlasT. PetroffD. SassoM. FanJ.G. MiY.Q. LédinghenD.V. KumarM. Lupsor-PlatonM. HanK.H. CardosoA.C. FerraioliG. ChanW.K. WongV.W.S. MyersR.P. ChayamaK. Friedrich-RustM. BeaugrandM. ShenF. HiriartJ.B. SarinS.K. BadeaR. JungK.S. MarcellinP. FiliceC. MahadevaS. WongG.L.H. CrottyP. MasakiK. BojungaJ. BedossaP. KeimV. WiegandJ. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.J. Hepatol.20176651022103010.1016/j.jhep.2016.12.02228039099
     [Google Scholar]
  30. MorseC.G. McLaughlinM. ProschanM. KohC. KleinerD.E. HellerT. KovacsJ.A. Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy.AIDS201529172297230210.1097/QAD.000000000000084126544701
     [Google Scholar]
  31. NewsomeP.N. SassoM. DeeksJ.J. ParedesA. BoursierJ. ChanW.K. YilmazY. CzernichowS. ZhengM.H. WongV.W.S. AllisonM. TsochatzisE. AnsteeQ.M. SheridanD.A. EddowesP.J. GuhaI.N. CobboldJ.F. ParadisV. BedossaP. MietteV. Fournier-PoizatC. SandrinL. HarrisonS.A. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study.Lancet Gastroenterol. Hepatol.20205436237310.1016/S2468‑1253(19)30383‑832027858
     [Google Scholar]
  32. FranchisD.R. BoschJ. Garcia-TsaoG. ReibergerT. RipollC. AbraldesJ.G. AlbillosA. BaigesA. BajajJ. BañaresR. BarrufetM. BenajibaL. BerzigottiA. BureauC. CalvarusoV. CardenasA. D’AmicoG. GottardiD.A. Dell’EraA. EscorsellA. FallowfieldJ. FerralH. FrancqueS. GabaR. Garcia-PagànJ.C. GenescàJ. RodriguesS.G. Gracia-SanchoJ. HanG. Hernandez-GeaV. JiaJ. KiladjianJ.J. KragA. LalemanW. MuraL.V. LensS. LuoX. MandorferM. MuradS.D. ParadisV. PatchD. PianoS. PinzaniM. PlessierA. PrimignaniM. ProcopetB. RautouP.E. RudlerM. SarinS.K. SchepisF. SenzoloM. ShahV. ShuklaA. TandonP. TellezL. ThabutD. ThieleM. TrebickaJ. TripathiD. TsochatzisE. TurcoL. TuronF. VallaD. VillanuevaC. WanlessI. YoshijiH. Baveno VII – Renewing consensus in portal hypertension.J. Hepatol.202276495997410.1016/j.jhep.2021.12.02235120736
     [Google Scholar]
  33. YounossiZ.M. KoenigA.B. AbdelatifD. FazelY. HenryL. WymerM. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016641738410.1002/hep.2843126707365
     [Google Scholar]
  34. LenthR.V. Java applets for power and sample size.Available from: http://www.stat.uiowa.edu/~rlenth/Power
  35. DuarteM. TienP. MaY. NoworolskiS.M. KornN. PriceJ.C. Controlled attenuation parameter accurately detects liver steatosis in people with HIV.AIDS202236152147215210.1097/QAD.000000000000335135950941
     [Google Scholar]
  36. VujanovićM. Brkić-JovanovićN. IlićD. DrvendžijaZ. Srdić-GalićB. TurkulovV. BrkićS. MarićD. Associations of visceral fat thickness and anthropometric measurements with non-alcoholic fatty liver disease development in male patients mono-infected with human immunodeficiency virus.South. Afr. J. HIV Med.201920196810.4102/sajhivmed.v20i1.96831534788
     [Google Scholar]
  37. MichelM. LabenzC. AndersM. WahlA. GirolsteinL. KapsL. KremerW.M. HuberY. GalleP.R. SprinzlM. SchattenbergJ.M. Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV.Hepatol. Commun.2022682011202110.1002/hep4.195835411570
     [Google Scholar]
  38. YounossiZ. AlkhouriN. CusiK. IsaacsS. KanwalF. NoureddinM. LoombaR. RavendhranN. LamB. NaderK. RacilaA. NaderF. HenryL. A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis.Aliment. Pharmacol. Ther.202357330431210.1111/apt.1734636511349
     [Google Scholar]
  39. YounossiZ.M. PaikJ.M. HenryL. StepanovaM. NaderF. Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care.Liver Int.2024liv.1611910.1111/liv.1611939373093
     [Google Scholar]
  40. MauriceJ.B. PatelA. ScottA.J. PatelK. ThurszM. LemoineM. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection.AIDS201731111621163210.1097/QAD.000000000000150428398960
     [Google Scholar]
  41. BaşaranN.Ç. İdilmanİ. TokuçoğluH.A. OnurM.R. SönmezerM.Ç. ÖzışıkL. KarçaaltıncabaM. İnkayaA.Ç. ÜnalS. Detection of non-alcoholic fatty liver disease with non-invasive tools in turkish people living with HIV and with apparently normal liver function.Curr. HIV Res.202321319220110.2174/1570162X2166623071412271637455457
     [Google Scholar]
  42. YilmazY. YilmazN. AtesF. KarakayaF. GokcanH. KayaE. The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study.Hepat. Forum.202122374210.14744/hf.2021.2020.0033
     [Google Scholar]
  43. DulaiP.S. SirlinC.B. LoombaR. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.J. Hepatol.20166551006101610.1016/j.jhep.2016.06.00527312947
     [Google Scholar]
  44. TamakiN. AjmeraV. LoombaR. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.Nat. Rev. Endocrinol.2022181556610.1038/s41574‑021‑00584‑034815553
     [Google Scholar]
  45. OedaS. TanakaK. OshimaA. MatsumotoY. SueokaE. TakahashiH. Diagnostic accuracy of fibroscan and factors affecting measurements.Diagnostics2020101194010.3390/diagnostics1011094033198092
     [Google Scholar]
  46. AjmeraV.H. CachayE.R. RamersC.B. BassirianS. SinghS. BettencourtR. RichardsL. HamiltonG. MiddletonM. FowlerK. SirlinC. LoombaR. Optimal threshold of controlled attenuation parameter for detection of HIV-associated NAFLD with magnetic resonance imaging as the reference standard.Clin. Infect. Dis.202172122124213110.1093/cid/ciaa42932975278
     [Google Scholar]
  47. LemoineM. AssoumouL. GirardP.M. ValantinM.A. KatlamaC. WitD.S. CampaP. RougierH. MeynardJ.L. NecsoiC. HuefnerA.D. LuzenV.J. WieschS.Z.J. BastardJ.P. FellahiS. MaussS. StankovM.V. BaumgartenA. PostG. SerfatyL. RatziuV. MenuY. SchlueJ. BedossaP. CapeauJ. CostagliolaD. BehrensG. IngilizP. Screening HIV patients at risk for nafld using MRI-PDFF and transient elastography: A european multicenter prospective study.Clin. Gastroenterol. Hepatol.2023213713722.e310.1016/j.cgh.2022.03.04835436624
     [Google Scholar]
  48. PerazzoH. CardosoS.W. YanavichC. NunesE.P. MorataM. GorniN. SilvaD.P.S. CardosoC. AlmeidaC. LuzP. VelosoV.G. GrinsztejnB. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy.J. Int. AIDS Soc.20182111e2520110.1002/jia2.2520130394678
     [Google Scholar]
  49. YanavichC. PachecoA.G. CardosoS.W. NunesE.P. ChavesU.S.B. FreitasG. SantosR. MorataM. VelosoV.G. GrinsztejnB. PerazzoH. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV.HIV Med.202122644545610.1111/hiv.1306033529485
     [Google Scholar]
  50. MilicJ. MenozziV. SchepisF. MalagoliA. BesuttiG. FranconiI. RaimondiA. CarliF. MussiniC. SebastianiG. GuaraldiG. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV.AIDS202034131915192110.1097/QAD.000000000000265033009010
     [Google Scholar]
  51. JongraksakT. SobhonslidsukA. JatchavalaJ. WarodomwichitD. KaewduangP. SungkanuparphS. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV- positive people.Int. J. STD AIDS202132326627510.1177/095646242096099733334267
     [Google Scholar]
  52. SharmaP. DhawanS. BansalR. TyagiP. BansalN. SinglaV. KumarA. MatinA. AroraA. The usefulness of transient elastography by FibroScan for the evaluation of liver fibrosis.Indian J. Gastroenterol.201433544545110.1007/s12664‑014‑0491‑x25138787
     [Google Scholar]
  53. LuiG. WongV.W.S. WongG.L.H. ChuW.C.W. WongC.K. YungI.M.H. WongR.Y.K. YeungS.L. YeungD.K.W. CheungC.S.K. ChanH.Y. ChanH.L.Y. LeeN. Liver fibrosis and fatty liver in Asian HIV-infected patients.Aliment. Pharmacol. Ther.201644441142110.1111/apt.1370227301337
     [Google Scholar]
  54. Vuille-LessardÉ. LebouchéB. LennoxL. RoutyJ.P. CostiniukC.T. PexosC. GiannakisA. SzaboJ. KleinM.B. SebastianiG. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.AIDS201630172635264310.1097/QAD.000000000000124127603289
     [Google Scholar]
  55. PriceJ.C. MaY. KuniholmM.H. AdimoraA.A. FischlM. FrenchA.L. GolubE.T. Konkle-ParkerD. MinkoffH. OfotokunI. PlankeyM. SharmaA. TienP.C. Human immunodeficiency virus is associated with elevated fibroscan–aspartate aminotransferase (FAST) score.Clin. Infect. Dis.202275122119212710.1093/cid/ciac33735511608
     [Google Scholar]
  56. AhmadA.K. AtzoriS. Taylor-RobinsonS.D. MauriceJ.B. CookeG.S. GarveyL. Spleen stiffness measurements using point shear wave elastography detects noncirrhotic portal hypertension in human immunodeficiency virus.Medicine20199847e1796110.1097/MD.000000000001796131764798
     [Google Scholar]
  57. WelzenV.B.J. MudrikovaT. IdrissiE.A. HoepelmanA.I.M. ArendsJ.E. A review of non-alcoholic fatty liver disease in HIV-infected patients: The next big thing?Infect. Dis. Ther.201981335010.1007/s40121‑018‑0229‑730607807
     [Google Scholar]
  58. LombardiR. SambatakouH. MariolisI. CokkinosD. PapatheodoridisG.V. TsochatzisE.A. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection.Dig. Liver Dis.201648121471147710.1016/j.dld.2016.08.11727623186
     [Google Scholar]
  59. BakasisA.D. AndroutsakosT. Liver fibrosis during antiretroviral treatment in HIV-infected individuals. truth or tale?Cells2021105121210.3390/cells1005121234063534
     [Google Scholar]
  60. BenmassaoudA. GhaliP. CoxJ. WongP. SzaboJ. DeschenesM. OsikowiczM. LeboucheB. KleinM.B. SebastianiG. Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection.PLoS One2018131e019198510.1371/journal.pone.019198529381754
     [Google Scholar]
  61. PezziniM.F. CheinquerH. AraujoD.A. Schmidt-CerskiC.T. SprinzE. Herz-WolffF. PoetaJ. Hepatic steatosis among people living with HIV in Southern Brazil: Prevalence and risk factors.Sci. Rep.2020101828210.1038/s41598‑020‑65133‑732427918
     [Google Scholar]
  62. Crum-CianfloneN. DilayA. CollinsG. AsherD. CampinR. MedinaS. GoodmanZ. ParkerR. LifsonA. CapozzaT. BavaroM. HaleB. HamesC. Nonalcoholic fatty liver disease among HIV-infected persons.J. Acquir. Immune Defic. Syndr.200950546447310.1097/QAI.0b013e318198a88a19225402
     [Google Scholar]
  63. KalligerosM. VassilopoulosA. ShehadehF. VassilopoulosS. LazaridouI. MylonakisE. PromratK. WandsJ.R. Prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV monoinfection: A systematic review and meta-analysis.Clin. Gastroenterol. Hepatol.20232171708172210.1016/j.cgh.2023.01.00136642292
     [Google Scholar]
  64. VermaS. JensenD. HartJ. MohantyS.R. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).Liver Int.20133391398140510.1111/liv.1222623763360
     [Google Scholar]
  65. SorrentinoP. TarantinoG. ConcaP. PerrellaA. TerraccianoM.L. VecchioneR. GargiuloG. GennarelliN. LobelloR. Silent non-alcoholic fatty liver disease—a clinical–histological study.J. Hepatol.200441575175710.1016/j.jhep.2004.07.01015519647
     [Google Scholar]
  66. NishijimaT. GatanagaH. ShimboT. KomatsuH. NozakiY. NagataN. KikuchiY. YanaseM. OkaS. Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection.PLoS One201491e8759610.1371/journal.pone.008759624498148
     [Google Scholar]
  67. MacíasJ. GonzálezJ. TuralC. Ortega-GonzálezE. PulidoF. RubioR. CifuentesC. Díaz-MenéndezM. JouA. RubioP. BurgosÁ. PinedaJ.A. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients.AIDS20142891279128710.1097/QAD.000000000000024824614088
     [Google Scholar]
  68. GuaraldiG. SquillaceN. StentarelliC. OrlandoG. D’AmicoR. LigabueG. FiocchiF. ZonaS. LoriaP. EspositoR. PalellaF. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: Prevalence, characteristics, and predictors.Clin. Infect. Dis.200847225025710.1086/58929418532884
     [Google Scholar]
  69. MichelM. LabenzC. WahlA. AndersM. ArmandiA. HuberY. GalleP.R. SprinzlM. SchattenbergJ.M. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.AIDS202236121665167410.1097/QAD.000000000000331235849074
     [Google Scholar]
  70. JanovskyC.C.P.S. CesenaF.H. ValenteV.A.T. ConceiçãoR.D.O. SantosR.D. BittencourtM.S. Association between thyroid-stimulating hormone levels and non-alcoholic fatty liver disease is not independent from metabolic syndrome criteria.Eur. Thyroid J.20187630230710.1159/00049232430574460
     [Google Scholar]
  71. EscudéM.A. PeraG. ArteagaI. ExpósitoC. RodríguezL. ToránP. CaballeriaL. Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population.Med. Clín.202015411631153607
     [Google Scholar]
  72. BanoA. ChakerL. PlompenE.P.C. HofmanA. DehghanA. FrancoO.H. JanssenH.L.A. MuradS.D. PeetersR.P. Thyroid function and the risk of nonalcoholic fatty liver disease: The rotterdam study.J. Clin. Endocrinol. Metab.201610183204321110.1210/jc.2016‑130027270473
     [Google Scholar]
  73. ChungG.E. KimD. KimW. YimJ.Y. ParkM.J. KimY.J. YoonJ.H. LeeH.S. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism.J. Hepatol.201257115015610.1016/j.jhep.2012.02.02722425701
     [Google Scholar]
  74. ChenY. TianS. WuJ. LiH. LiS. XuZ. LiangX. AdhikariV.P. XiaoJ. SongJ. MaC. SheR. LiZ. WuK. KongL. Impact of thyroid function on the prevalence and mortality of metabolic dysfunction-associated fatty liver disease.J. Clin. Endocrinol. Metab.20231087e434e44310.1210/clinem/dgad01636637992
     [Google Scholar]
  75. ElshinshawyS. ElhaddadH. AlemA.S. ShakerO. SalamR. YosryA. ElebrashyI. The interrelation between hypothyroidism and non-alcoholic fatty liver disease, a cross-sectional study.J. Clin. Exp. Hepatol.202313463864810.1016/j.jceh.2023.03.00437440948
     [Google Scholar]
  76. HuY. ZhouF. LeiF. LinL. HuangX. SunT. LiuW. ZhangX. CaiJ. SheZ.G. LiH. The nonlinear relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease.Front. Endocrinol.202314111535410.3389/fendo.2023.111535436909326
     [Google Scholar]
  77. KarimG BansalMB Resmetirom: An orally administered, smallmolecule, liver-directed, beta-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.touchREV Endocrinol.20231916070
     [Google Scholar]
  78. Vidal-CevallosP. Murúa-Beltrán GallS. UribeM. Chávez-TapiaN.C. Understanding the relationship between nonalcoholic fatty liver disease and thyroid disease.Int. J. Mol. Sci.202324191460510.3390/ijms24191460537834051
     [Google Scholar]
  79. RinellaM.E. LazarusJ.V. RatziuV. FrancqueS.M. SanyalA.J. KanwalF. RomeroD. AbdelmalekM.F. AnsteeQ.M. ArabJ.P. ArreseM. BatallerR. BeuersU. BoursierJ. BugianesiE. ByrneC.D. NarroC.G.E. ChowdhuryA. Cortez-PintoH. CryerD.R. CusiK. El-KassasM. KleinS. EskridgeW. FanJ. GawriehS. GuyC.D. HarrisonS.A. KimS.U. KootB.G. KorenjakM. KowdleyK.V. LacailleF. LoombaR. Mitchell-ThainR. MorganT.R. PowellE.E. RodenM. Romero-GómezM. SilvaM. SinghS.P. SookoianS.C. SpearmanC.W. TiniakosD. ValentiL. VosM.B. WongV.W.S. XanthakosS. YilmazY. YounossiZ. HobbsA. Villota-RivasM. NewsomeP.N. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.Hepatology20237861966198610.1097/HEP.000000000000052037363821
     [Google Scholar]
  80. YilmazY. The heated debate over NAFLD renaming: An ongoing saga.Hepat. Forum.2023438991
     [Google Scholar]
  81. GawriehS. Vilar-GomezE. WoretaT.A. LakeJ.E. WilsonL.A. PriceJ.C. NaggieS. SterlingR.K. HeathS. CoreyK.E. CachayE.R. AjmeraV. TonasciaJ. SulkowskiM.S. ChalasaniN. LoombaR. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.Aliment. Pharmacol. Ther.202459566667910.1111/apt.1784938158589
     [Google Scholar]
  82. YilmazY. ZeybelM. AdaliG. CosarA.M. SertesenE. GokcanH. TASL practice guidance on the clinical assessment and management of patients with nonalcoholic fatty liver disease.Hepat. Forum.20234Suppl 113210.14744/hf.2023.2023.0011
     [Google Scholar]
  83. ParsaA.A. BhangooA. HIV and thyroid dysfunction.Rev. Endocr. Metab. Disord.201314212713110.1007/s11154‑013‑9248‑623743889
     [Google Scholar]
  84. HarsløfM. KnudsenA.D. BenfieldT. NordestgaardB.G. Feldt-RasmussenU. NielsenS.D. No evidence of increased risk of thyroid dysfunction in well treated people living with HIV.AIDS201832152195219910.1097/QAD.000000000000195430005023
     [Google Scholar]
/content/journals/chr/10.2174/011570162X340918250312040500
Loading
Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in People Living with HIV-1
Cur. HIV Res. 23, 121 (2025); https://doi.org/10.2174/011570162X340918250312040500
/content/journals/chr/10.2174/011570162X340918250312040500
/content/journals/chr/10.2174/011570162X340918250312040500
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): AIDS; fibrosis; HIV; MASLD; NAFLD; NASH; transient elastography

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test